Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes

Immunology

Volumn 142, Issue 4, 2014, Pages 551-561

  Ikebuchi, Ryoyo ^a   Konnai, Satoru ^a   Okagawa, Tomohiro ^a   Yokoyama, Kazumasa ^b   Nakajima, Chie ^b   Suzuki, Yasuhiko ^b   Murata, Shiro ^a   Ohashi, Kazuhiko ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Bovine immunology; Cell death; Immunoglobulin fusion protein; Programmed death ligand 1

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 IMMUNOGLOBULIN; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL LINE; CELL MEMBRANE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; COS 7 CELL LINE; CROSS LINKING; CYTOKINE PRODUCTION; GENETIC TRANSFECTION; HELA CELL LINE; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INTERFERON PRODUCTION; LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

BOVINE IMMUNOLOGY; CELL DEATH; IMMUNOGLOBULIN FUSION PROTEIN; PROGRAMMED DEATH-LIGAND 1;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD274; B-LYMPHOCYTES; CATTLE; CELL DEATH; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; CRICETULUS; HELA CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC CAPPING; INTERFERON-GAMMA;

EID: 84903899240     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12243     Document Type: Article

References (35)

1. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007; 56:739-45.
2. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704.
3. Hori J, Wang M, Miyashita M et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol 2006; 177:5928-35.
4. Nomi T, Sho M, Akahori T et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13:2151-7.
5. Salama AD, Chitnis T, Imitola J et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003; 198:71-8.
6. + T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-202.
7. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75.
8. Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14:3044-51.
9. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 1:1-6.
10. Jazayeri JA, Carroll GJ. Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs 2008; 22:11-26.
11. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002; 296:1323-6.
12. Geng H, Zhang G-M, Xiao H et al. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int J Cancer 2006; 118:2657-64.
13. He Y-F, Zhang G-M, Wang X-H, Zhang H, Yuan Y, Li D, Feng Z-H. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol 2004; 173:4919-28.
14. Wan B, Nie H, Liu A, Feng G. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 2006; 177:8844-50.
15. + T cell activation. Eur J Immunol 2006; 36:2472-82.
16. Dong H, Strome SE, Matteson EL et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 2003; 111:363-70.
17. Kim Y, Park G, Lee H, Song H, Choi I-H, Lee JW, Hur YD. Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen species production, JNK signaling activation, and fasL expression. J Immunol 2008; 181:6158-69.
18. Ikebuchi R, Konnai S, Shirai T, Sunden Y, Murata S, Onuma M, Ohashi K. Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade. Vet Res 2011; 42:103.
19. Pulko V, Harris KJ, Liu X, Gibbons RM, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-H1 expressed by activated CD8 T cells is essential for their survival. J Immunol 2011; 187:5606-14.
20. Zinselmeyer BH, Heydari S, Sacristán C et al. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med 2013; 210:757-74.
21. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27:111-22.
22. Butte MJ, Pena-Cruz V, Kim M-J, Freeman GJ, Sharpe AH. Interaction of human PD-L1 and B7-1. Mol Immunol 2008; 45:3567-72.
23. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5:1365-9.
24. Subudhi S, Zhou P, Yerian L et al. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest 2004; 113:694-700.
25. Saudemont A, Jouy N, Hetuin D, Quesnel B. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 2005; 105:2428-35.
26. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108:193-9.
27. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fc gamma receptor I binding and monocyte triggering activities. Eur J Immunol 1999; 29:2613-24.
28. Shields RL, Namenuk AK, Hong K et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 2001; 276:6591-604.
29. Ikebuchi R, Konnai S, Okagawa T, Yokoyama K, Nakajima C, Suzuki Y, Murata S, Ohashi K. Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells in vitro. Vet Res 2013; 44:59.
30. Hase M, Yokomizo T, Shimizu T, Nakamura M. Characterization of an orphan G protein-coupled receptor, GPR20, that constitutively activates Gi proteins. J Biol Chem 2008; 283:12747-55.
31. Sasaki F, Okuno T, Saeki K, Min L, Onohara N, Kato H, Shimizu T, Yokomizo T. A high-affinity monoclonal antibody against the FLAG tag useful for G-protein-coupled receptor study. Anal Biochem 2012; 425:157-65.
32. Paterson AM, Brown KE, Keir ME et al. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol 2011; 187:1097-105.
33. Ghiotto M, Gauthier L, Serriari N, Pastor S, Truneh A, Nunes JA, Olive D. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol 2010; 22:651-60.
34. Mkrtichyan M, Najjar YG, Raulfs EC, Liu L, Langerman S, Guittard G, Ozbun L, Khleif SN. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J Immunol 2012; 189:2338-47.
35. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008; 111:3635-43.